Apellis Pharmaceuticals, Inc. Common Stock
APLS
$41.03
-0.07%
Apellis Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing and commercializing novel therapeutics that inhibit the complement system at the C3 protein level. The company is a recognized leader in complement inhibition with two marketed drugs, SYFOVRE and EMPAVELI, targeting diseases with high unmet needs. The current investor narrative is dominated by the recent completion of its acquisition by Biogen, a strategic blockbuster deal that provides immediate revenue diversification for Biogen and long-term pipeline potential, shifting the focus from Apellis as a standalone entity to its integration and future growth within a larger biopharma platform.…
APLS
Apellis Pharmaceuticals, Inc. Common Stock
$41.03
Related headlines
Investment Opinion: Should I buy APLS Today?
Rating & Thesis: Hold. The investment thesis is that APLS, as a newly acquired subsidiary of Biogen, offers limited standalone upside or downside from the current price, as its value is now effectively set by the acquisition terms and its future is tied to Biogen's execution.
Supporting Evidence: The stock trades at a trailing PS ratio of 3.15, which is a massive de-rating from its historical highs above 15, suggesting the market now values it as a commercial asset rather than a speculative biotech. Analyst revenue estimates for the next period average a substantial $1.54 billion, implying a forward PS of approximately 2.06, which prices in growth. However, recent quarterly revenue declined -5.94% YoY, and profitability remains elusive with a Q4 net loss. The stock trades at its 52-week high, leaving little margin for error.
Risks & Conditions: The two biggest risks are failure to achieve revenue estimates within Biogen and a post-acquisition sentiment shift leading to multiple compression. This Hold rating would upgrade to a Buy only if Biogen demonstrates clear, accelerated commercial synergy in the next 1-2 quarters, driving revenue growth above estimates and stabilizing profitability. It would downgrade to a Sell if quarterly revenue declines persist post-acquisition or if the stock breaks significantly below key technical support levels, indicating a loss of confidence in the deal's strategic value. The stock is fairly valued relative to its new reality as an acquired entity, but not undervalued enough to warrant a Buy.
Sign up to view all
APLS 12-Month Price Forecast
The 12-month outlook for APLS is one of consolidation and integration. The bullish scenario requires flawless execution and synergy realization by Biogen, which is possible but not the base case. The most likely outcome (60% probability) is a period of stable, range-bound trading as Apellis operates within Biogen, meeting but not exceeding expectations. The bear case, while lower probability, carries significant downside risk back to the $30s if integration stumbles. The stance is neutral because the stock's fate is now largely tied to Biogen's corporate execution, removing Apellis's standalone catalyst potential. We would upgrade to bullish on evidence of revenue re-acceleration and margin expansion under Biogen; we would downgrade to bearish on consecutive quarterly misses or guidance reductions.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Apellis Pharmaceuticals, Inc. Common Stock's 12-month outlook, with a consensus price target around $53.34 and implied upside of +30.0% versus the current price.
Average Target
$53.34
6 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
6
covering this stock
Price Range
$33 - $53
Analyst target range
Insufficient current analyst coverage and target data is available post the acquisition completion. The provided data shows 9 analysts with revenue and EPS estimates, but no consensus price target or recommendation breakdown is supplied. This is typical following a definitive acquisition agreement, as coverage often ceases or becomes moot once a deal is announced and the stock price converges to the acquisition price. The implications are clear: with the acquisition by Biogen completed, the stock's price discovery is now effectively tied to the deal terms rather than independent analyst models, leading to reduced volatility and a cessation of traditional equity research coverage. The institutional ratings data, all from 2024, is historical and predates the acquisition announcement, rendering it irrelevant for current sentiment analysis.
Drowning in data?
Find the real signal!
Bulls vs Bears: APLS Investment Factors
The evidence is currently balanced but leans bearish on a standalone, forward-looking basis. The bullish case is heavily anchored on the completed acquisition by Biogen, which provides strategic safety and a valuation floor. The bearish case highlights Apellis's fundamental challenges: inconsistent profitability, recent revenue decline, and a significant valuation de-rating from its high-growth phase. The single most important tension in the investment debate is the resolution of Apellis's commercial execution within Biogen. Can Biogen stabilize the volatile revenue and drive consistent profitability from the high-margin products, or will the integration challenges and underlying commercial lumpiness persist? The outcome of this integration will determine whether the stock remains a stable asset or faces further de-rating.
Bullish
- Completed Acquisition by Biogen: The acquisition by Biogen, a larger biopharma platform, provides immediate revenue diversification and long-term pipeline support. The stock price has converged to the deal terms, providing a floor and eliminating standalone execution risk.
- Strong Gross Margin of 85.1%: The company's Q4 2025 gross margin of 85.13% indicates a highly profitable commercial product profile for its marketed drugs. This provides a strong foundation for future earnings as revenue scales and operating expenses are better controlled.
- Positive Free Cash Flow Generation: Apellis generated $45.33 million in free cash flow over the trailing twelve months, demonstrating its commercial products can fund operations. This reduces reliance on external financing and supports the business within Biogen's portfolio.
- Significant Revenue Scale: The company has achieved substantial commercial revenue, with analyst estimates averaging $1.54 billion for the next period. This scale validates the market demand for its complement inhibitors and provides a solid base for Biogen.
Bearish
- Inconsistent Profitability & Quarterly Loss: Despite high revenue, the company reported a net loss of -$58.95 million in Q4 2025, with a trailing net margin of only 2.23%. Quarterly earnings swing wildly, indicating high operating expenses and non-recurring income items.
- Recent Quarterly Revenue Decline of -5.94%: Q4 2025 revenue of $199.9 million represents a -5.94% year-over-year decline, raising concerns about near-term growth trajectory. This follows a volatile pattern, with revenue dropping sharply from $458.6 million in Q3 2025.
- Valuation De-Rating from Historical Highs: The stock's trailing PS ratio of 3.15 is a dramatic compression from its historical PS of 15.84 (Q4 2025) and 18.60 (Q4 2024). This reflects a market shift from valuing pipeline potential to commercial execution, which has been choppy.
- Lack of Independent Analyst Coverage: Post-acquisition, there is insufficient current analyst coverage and price targets, as the stock's value is now tied to deal terms. This reduces price discovery and independent validation of the business's standalone prospects.
APLS Technical Analysis
The stock is in a powerful, sustained uptrend, evidenced by a staggering 1-year price change of +137.44%. The current price of $41.03 sits at 99.7% of its 52-week high of $41.14, indicating the stock is trading at its absolute peak. This positioning near the highs reflects extreme momentum but also suggests the stock is fully valued on a technical basis, with little room for error before encountering significant resistance. Recent short-term momentum is exceptionally strong, with a 3-month price change of +86.08% and a 1-month change of +0.47%. The massive 3-month surge, which dramatically outpaces the S&P 500's 9.74% gain, is directly attributable to the acquisition announcement and completion, while the flattening 1-month momentum suggests the stock has entered a consolidation phase post-deal closure, digesting its monumental gains. Key technical support is at the 52-week low of $16.10, while immediate resistance is at the 52-week high of $41.14. A breakout above this level would signal continued bullish conviction, though it is a nominal move from the current price. The stock's beta of -0.246 is anomalous and indicates its price movement has been negatively correlated with the broader market over the measured period, a characteristic often seen during event-driven, company-specific catalysts like an acquisition, which decouples the stock from macro trends.
Beta
-0.25
-0.25x market volatility
Max Drawdown
-43.5%
Largest decline past year
52-Week Range
$17-$41
Price range past year
Annual Return
+137.4%
Cumulative gain past year
| Period | APLS Return | S&P 500 |
|---|---|---|
| 1m | +0.5% | +3.3% |
| 3m | +86.1% | +6.9% |
| 6m | +101.8% | +12.4% |
| 1y | +137.4% | +23.4% |
| ytd | +58.7% | +7.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
APLS Fundamental Analysis
Revenue growth has been volatile but shows significant commercial scale, with the most recent quarterly revenue at $199.9 million, though this represents a -5.94% year-over-year decline. Segment data reveals the business is overwhelmingly driven by product sales, which constituted $190.3 million (95.2%) of total revenue in Q4 2025, compared to only $9.6 million from licensing. The quarterly trend is choppy; revenue surged to $458.6 million in Q3 2025 before dropping back, indicating potential lumpiness in product uptake or one-time items affecting reported sales. The company's path to profitability is inconsistent; it reported a net loss of -$58.95 million in Q4 2025, despite a robust gross margin of 85.13%. For the full year, the picture is mixed with a trailing twelve-month net income of $7.07 million (a net margin of 2.23%), but quarterly results swing wildly from a $215.7 million profit in Q3 to losses in other quarters, highlighting the non-recurring nature of some income and ongoing high operating expenses. The balance sheet shows moderate financial leverage with a debt-to-equity ratio of 1.31, but strong liquidity is evidenced by a current ratio of 3.14. The company generated positive free cash flow over the trailing twelve months of $45.33 million, providing internal funding flexibility. However, an ROE of 6.05% indicates modest returns on shareholder equity, suggesting the business is not yet generating highly efficient profits from its capital base post its commercial launch phase.
Quarterly Revenue
$199913000.0B
2025-12
Revenue YoY Growth
-5.94%
YoY Comparison
Gross Margin
85.13%
Latest Quarter
Free Cash Flow
$45327000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is APLS Overvalued?
Given the company's inconsistent profitability, with a trailing net income of $7.07 million, we lead with the Price-to-Sales (PS) ratio as the primary valuation metric, as earnings are not yet a stable foundation for valuation. The stock trades at a trailing PS ratio of 3.15 and a forward PS ratio that can be implied from analyst estimates; with a market cap of $3.17 billion and estimated revenue of $1.54 billion, the forward PS is approximately 2.06, suggesting the market expects significant revenue growth to justify the current price. Peer comparison is challenging without explicit industry averages provided, but the current trailing PS of 3.15 for a commercial-stage biotech with nearly $2 billion in annualized revenue could be considered reasonable if growth expectations are high, though we lack a sector benchmark for precise premium/discount analysis. Historically, the stock's own valuation has compressed significantly from extreme levels; its current PS ratio of 3.15 is far below its historical PS of 15.84 from Q4 2025 and 18.60 from Q4 2024. This dramatic de-rating reflects the market's shift from valuing Apellis on long-dated pipeline potential to valuing it as a commercial entity with acquired revenue streams, and more recently, its value being set by the acquisition terms from Biogen.
PE
141.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -30x~3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
45.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Apellis faces significant financial risks stemming from its inconsistent path to profitability. Despite a robust gross margin of 85.13%, the company reported a Q4 2025 net loss of -$58.95 million, highlighting high and volatile operating expenses. Revenue concentration in product sales (95.2% of total) and quarterly volatility—with revenue swinging from $458.6 million in Q3 to $199.9 million in Q4—indicate potential lumpiness in drug uptake or one-time items, making earnings forecasts unreliable. The debt-to-equity ratio of 1.31 shows moderate financial leverage, though strong liquidity (current ratio of 3.14) mitigates near-term solvency risk.
Market & Competitive Risks: The primary market risk is valuation compression, as the stock has already de-rated massively from a historical PS of 18.60 to 3.15. Trading at 99.7% of its 52-week high, any disappointment could trigger a sharp correction. The anomalous beta of -0.246 indicates the stock's recent performance was entirely event-driven (the acquisition), decoupling it from the market; this correlation may normalize post-deal, reintroducing macro sensitivity. Competitive and regulatory risks in the biotechnology sector remain ever-present for its complement inhibitor franchise.
Worst-Case Scenario: The worst-case scenario involves Biogen encountering unforeseen integration difficulties, leading to a deterioration of Apellis's commercial momentum and a failure to achieve projected revenue of $1.54 billion. This could trigger a re-assessment of the acquisition's value, causing the stock to fall towards its pre-deal trading range. The realistic downside is significant, referencing the 52-week low of $16.10, which would represent a loss of approximately -61% from the current price of $41.03. A more probable adverse scenario might see a pullback to the $30-$35 range if quarterly results underperform within the new parent company.
FAQ
The key risks are: 1) Integration Risk: The commercial and operational success of Apellis within Biogen is unproven; missteps could hurt revenue. 2) Financial Risk: Despite scale, profitability is inconsistent (Q4 2025 net loss of -$58.95M), and the debt-to-equity ratio of 1.31 indicates leverage. 3) Commercial Execution Risk: Quarterly revenue is volatile, with a -5.94% YoY decline last quarter, questioning near-term growth. 4) Valuation Risk: Trading at 99.7% of its 52-week high, the stock is technically extended and vulnerable to a pullback on any negative news. Integration risk is currently the most severe, as it directly impacts the investment's core thesis.
The 12-month forecast centers on a base case target range of $38-$41 (60% probability), reflecting stable post-acquisition trading. The bull case (25% probability) targets $42-$45, requiring Biogen to drive superior growth and synergies. The bear case (15% probability) sees a drop to $30-$36 if integration falters or commercial performance weakens. The most likely scenario is the base case, which assumes Apellis meets analyst revenue estimates of ~$1.54 billion under Biogen without major surprises. The key assumption is that the acquisition closes the valuation discovery process, leading to reduced volatility.
APLS appears fairly valued relative to its new status as an acquired entity. The trailing Price-to-Sales (PS) ratio of 3.15 represents a massive de-rating from its historical PS multiples above 15, indicating the market now values it as a commercial-stage company, not a speculative pipeline. Based on analyst revenue estimates of $1.54 billion, the forward PS is approximately 2.06, which is reasonable for a biotech with its scale and gross margins (85.13%). The valuation implies the market expects steady, but not explosive, revenue growth under Biogen's stewardship and is not pricing in significant multiple expansion from here.
APLS is not a compelling buy at current levels for most investors. The stock has surged 137% over the past year due to its acquisition by Biogen and now trades at its 52-week high, leaving little immediate upside. While the acquisition provides a valuation floor, the company's standalone fundamentals are mixed, with a recent quarterly revenue decline of -5.94% and inconsistent profitability. It could be a good buy for a patient investor already bullish on Biogen's overall strategy, seeking exposure to the complement franchise. However, for those seeking growth or value, better opportunities likely exist elsewhere until post-integration results are demonstrated.
APLS is more suitable for a long-term investment horizon aligned with Biogen's strategic timeline. The short-term, event-driven trade (the acquisition) is largely complete. As a part of Biogen, Apellis's value will be realized through long-term commercial execution, pipeline development, and potential synergies. The stock's anomalous beta of -0.246 will likely normalize, reintroducing market correlation over time. Given the need to see several quarters of integrated results, a minimum holding period of 12-18 months is suggested to properly evaluate the investment. It is not suitable for short-term trading due to reduced catalyst visibility and potential low volatility post-deal.
